Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer

Chemotherapy

Volumn 58, Issue 1, 2012, Pages 8-18

  Weycker, Derek ^a   Edelsberg, John ^a   Kartashov, Alex ^a   Barron, Rich ^b   Lyman, Gary ^c  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Costs and cost analysis; Febrile neutropenia; Metastatic breast cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NEUTROPENIC COMPLICATION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DATABASES, FACTUAL; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PACLITAXEL; RETROSPECTIVE STUDIES; RISK FACTORS; TAXOIDS;

EID: 84856939667     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000335604     Document Type: Article

References (37)

1. American Cancer Society, Inc., Surveillance and Health Policy Research. http:www.cancer. org (accessed November 29, 2009).
2. Honig SF: Hormonal therapy and chemotherapy; in Harris JR, Morrow M, Lippman ME, et al (eds): Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp 669-734.
3. Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152-1162.
4. Rastelli F, Crispino S: Factors predictive of response to hormone therapy in breast cancer. Tumori 2008; 94: 370-383.
5. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998; 339: 974-984.
6. Higgins MJ, Wolff AC: Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) 2008; 22: 614-629.
7. Isakoff S: Triple-negative breast cancer: Role of specific chemotherapy agents. Cancer J 2010; 16: 53-61.
8. Wilcken N, Hornbuckle J, Ghersi D: Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003; 2:CD002747.
9. Conlin AK, Seidman AD: Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: Current status and future opportunities. Clin Breast Cancer 2008; 8: 215-223.
10. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT: Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103: 1916-1924.
11. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-205.
12. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, et al: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005; 330: 217.
13. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low-dose intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 2003; 21: 4524-4531.
14. Kwak LW, Halpern J, Olshen RA, Horning SJ: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-977.
15. Cardoso F, Bedard PL, Winer EP, et al: International guidelines for management of metastatic breast cancer: Combination versus sequential single-agent chemotherapy. J Natl Cancer Inst 2009; 101: 1174-1181.
16. Mao W, Guan X, Tucker S, et al: Second-line combination chemotherapy with vinorelbine and capecitabine in patients with advanced breast cancer previously treated with anthracyclines and/or taxanes. Chemotherapy 2011; 57: 71-76.
17. Taguchi T, Nakayama T, Masuda N, et al: Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 2010; 56: 166-170.
18. Somali I, Alacacioglu A, Tarhan M, et al: Cisplatin plus gemcitabine chemotherapy in taxane/ anthracycline-resistant metastatic breast cancer. Chemotherapy 2009; 55: 155-160.
19. Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA: Health care costs for the treatment of breast cancer recurrent events: Estimates from a UK-based patient-level analysis. Br J Cancer 2007; 97: 479-485.
20. Smith TJ, Hillner BE: Bending the cost curve in cancer care. N Engl J Med 2011; 364: 2060-2065.
21. Stokes ME, Muehlenbein CE, Marciniak MD, et al: Neutropenia-related costs in patients with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009; 15: 669-682.
22. Kuderer NM, Dale DC, Crawford J, Cosler LE, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-2266.
23. Lyman GH, Kuderer N, Greene J, Balducci L: The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer 1998; 34: 1857-1864.
24. Code of Federal Regulations: Title 45 Public Welfare, Part 46: Protection of Human Subjects. 46.101.
25. Stokes ME, Thompson D, Montoya EL, et al: Ten-year survival and cost following breast cancer recurrence: Estimates from SEERMedicare data. Value Health 2008; 11: 213-220.
26. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Myeloid growth factors, v1.2010. http:// www.nccn.org/ professionals/physician-gls/ PDF/myeloid-growth.pdf.
27. Biganzoli L, Cufer T, Coleman BR, et al: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002; 20: 3114-3121.
28. Nabholtz JM, Falkson C, Campos D, et al: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as firstline chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21: 968-975.
29. Cosler LE, Sivasubramaniam V, Agboola O, et al: Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005; 8: 47-52.
30. Ramsey SD, Liu Z, Boer R, et al: Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2009; 12: 217-225.
31. Chen-Hardee S, Chrischilles EA, Voelker MD, et al: Population-based assessment for hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 2006; 17: 647-654.
32. Green MD, Koelbl H, Baselga J, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
33. Holmes FA, Jones SE, O'Shaughnessy J, et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
34. Elting LS, Lu C, Escalante CP, et al: Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26: 606-611.
35. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G: Cost of neutropenic complications of chemotherapy. Ann Oncol 2008; 19: 454-460.
36. Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, et al: Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study. Clin Ther 2009; 31: 1069-1081.
37. Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, et al: Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 2009; 115: 4839-4848.